CSF complement 3 and factor H are staging biomarkers in Alzheimer’s disease

INTRODUCTION: CSF levels of established Alzheimer’s disease (AD) biomarkers remain stable despite disease progression, and non-amyloid non-tau biomarkers have the potential of informing disease stage and progression. We previously identified complement 3 (C3) to be decreased in AD dementia, but this...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, William T., Watts, Kelly D., Tailor, Prashant, Nguyen, Trung P., Howell, Jennifer C., Lee, Raven C., Seyfried, Nicholas T., Gearing, Marla, Hales, Chadwick M., Levey, Allan I., Lah, James J., Lee, Eva K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4758165/
https://www.ncbi.nlm.nih.gov/pubmed/26887322
http://dx.doi.org/10.1186/s40478-016-0277-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4758165/
https://www.ncbi.nlm.nih.gov/pubmed/26887322
http://dx.doi.org/10.1186/s40478-016-0277-8

Ejemplares similares